Is Simparica Trio Safe? FDA Warning and Side Effects

Simparica Trio is approved by the FDA and considered safe for most dogs when used as directed, but it carries a class-wide FDA alert about potential neurological side effects that every dog owner should understand before starting the medication. The product combines three active ingredients to cover fleas, ticks, heartworm, and certain intestinal worms in a single monthly chewable, and in clinical trials and field studies it has been generally well tolerated. Still, “safe” in veterinary medicine does not mean “zero risk,” and the specifics of that risk depend on your dog’s age, weight, breed, and health status.

What the FDA Warning Actually Says

In September 2018, the FDA issued an alert to pet owners and veterinarians about potential neurological adverse events in dogs and cats treated with any drug in the isoxazoline class. Simparica Trio’s flea-and-tick ingredient, sarolaner, belongs to that class. Following the alert, the FDA requested that manufacturers of all isoxazoline products update their labels to highlight neurological events, because the reports appeared consistently across the entire class rather than being linked to one product alone.¹

The neurological events flagged by the FDA include muscle tremors, wobbliness (ataxia), and seizures. These are uncommon, but they are serious when they occur. The FDA did not pull any isoxazoline product from the market. Instead, it chose the less dramatic but still meaningful step of requiring clearer labeling so that veterinarians and owners can weigh the risks with better information. If your dog has a history of seizures or a known neurological condition, the updated labels specifically advise caution and a conversation with your vet before using any isoxazoline product.

How the Drug Works and Why Mammals Are Usually Spared

Sarolaner, the isoxazoline in Simparica Trio, kills fleas and ticks by blocking a type of nerve receptor in invertebrates called GABA receptors. When those receptors are blocked, the parasite’s nervous system goes haywire and the bug dies. The safety margin for mammals exists because isoxazolines bind much more weakly to mammalian GABA receptors than to insect and arachnid ones. Laboratory testing on human and canine GABA receptors found that sarolaner produced only moderate inhibition of GABA current at concentrations far above what a dog would encounter from a normal dose. In the same experiments, lotilaner (a different isoxazoline) showed even less activity on mammalian receptors, while fluralaner showed the strongest mammalian binding of the group.²

This selectivity is the whole reason the drug can work in the first place: it hammers the parasite’s nervous system at doses that barely register in a dog’s. But “barely register” is not the same as zero. At very high concentrations or in animals whose nervous systems are more vulnerable for other reasons, the drug can spill over into mammalian GABA receptor territory and cause the tremors or seizures described in the FDA alert. That is the pharmacological basis for why neurological events are rare but not impossible.

Common Side Effects You Might See

In safety studies, Simparica Trio was generally well tolerated even at elevated doses. In a controlled study that tested the product at both the standard dose and three times the standard dose in heartworm-infected dogs, the most frequently noted reactions were occasional vomiting and abnormal stool. Vomiting occurred at low rates across all groups, including the untreated control group, which means some of those episodes probably had nothing to do with the drug. A brief fever above 104 °F was recorded in two dogs the day after their first dose and resolved by the following day. No severe hypersensitivity reactions occurred during the study.³

In a separate field study evaluating the product against intestinal worm infections in real-world veterinary patients in Europe and the United States, the chewable tablet was described as well tolerated.⁴ A study looking at its use against a lung-dwelling worm found it was similarly well tolerated after a single treatment.⁵

So the everyday side effects most owners encounter, if any, tend to be gastrointestinal: a soft stool, a single episode of vomiting, maybe some temporary decreased appetite. These are the kind of mild reactions that happen with many oral medications and usually clear up on their own.

Puppies, Small Dogs, and Minimum Requirements

Simparica Trio is labeled for dogs as young as eight weeks of age weighing at least about 2.8 pounds (1.25 kg).⁶ That minimum weight matters because the chewable tablets come in fixed-dose sizes. The smallest whole tablet that can be given corresponds to dogs weighing at least about 1.3 kg in the clinical study population, and going below that threshold means the smallest available tablet delivers a proportionally larger dose per pound of body weight.⁴

For very young puppies or toy breeds hovering near that cutoff, weigh your dog at the vet rather than estimating at home. A few ounces of error in a two-pound puppy can meaningfully shift the dose-per-kilogram the puppy receives. Your vet can also advise whether the puppy is old enough and robust enough to start a combination product or whether a simpler, single-ingredient option makes sense as a first step.

Breed-Related Genetic Sensitivity

Some dog breeds carry a mutation in the ABCB1 gene (previously called MDR1). This gene normally produces a protein that acts as a gatekeeper at the blood-brain barrier, pumping certain drugs out of the brain before they can accumulate to dangerous levels. Dogs with the mutation have a leaky gatekeeper, which means drugs that would normally stay at safe concentrations in the brain can build up and cause neurological toxicity.

Breeds most commonly associated with the ABCB1 mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, and various Collie crosses, though it can appear in other breeds too. The mutation is best documented for macrocyclic lactone drugs like ivermectin, where affected dogs can experience severe neurological toxicity at higher doses used for conditions like mange, even though the same drugs are safe at the lower doses used for routine heartworm prevention.⁷ Moxidectin, one of the three ingredients in Simparica Trio, is a macrocyclic lactone, though it has a wider safety margin in ABCB1-affected dogs compared to ivermectin.⁸

Whether the isoxazoline component (sarolaner) poses added risk specifically in ABCB1-mutant dogs is less well studied. The FDA neurological warning applies to all dogs regardless of breed. If you own a breed known to carry the mutation, a genetic test can confirm your dog’s status, and your vet can factor the result into their recommendation. At standard heartworm-prevention doses, the moxidectin in Simparica Trio is at the lower end of the dosing range where problems with ABCB1-mutant dogs have been documented, but the combination of two potentially neuroactive ingredients in one tablet is worth discussing with your veterinarian if your dog tests positive for the mutation.

Giving Simparica Trio to a Heartworm-Positive Dog

One of Simparica Trio’s selling points is that it prevents heartworm infection, but prevention and treatment are very different things. If a dog already has an active heartworm infection with adult worms living in the heart and pulmonary arteries, giving a heartworm preventive can trigger rapid death of microfilariae (the larval worms circulating in the blood). That mass die-off can cause serious clinical complications, including blood clot formation in the lungs and anaphylactic-type shock.³

This is why every reputable veterinarian will test a dog for heartworm before starting any preventive, including Simparica Trio. If your dog tests positive, treating the existing infection comes first, and that treatment (typically involving melarsomine injections and a lengthy exercise restriction protocol) is a separate, more complex process. Starting a monthly preventive on top of an active infection without veterinary guidance is one of the genuinely dangerous misuses of these products.

Safety data from a controlled study of Simparica Trio given to dogs with existing heartworm infections did not show severe hypersensitivity reactions, and the product was described as generally well tolerated even at three times the label dose in that setting. But a controlled study with veterinary monitoring is very different from handing your dog a chewable at home without knowing the worm burden. The takeaway is straightforward: test first, every time, even if your dog has been on prevention and you are just switching products.

How the FDA Keeps Watching After Approval

A drug being FDA-approved does not mean the safety story is finished. The FDA’s Center for Veterinary Medicine runs a pharmacovigilance system that continuously collects reports of adverse drug experiences from veterinarians, pet owners, and manufacturers. Every report is evaluated by a veterinarian using a standardized algorithm and entered into a database. When a pattern emerges that suggests a public or animal health risk, the response can range from a safety communication or a labeling change all the way to pulling a product from the market or revoking its approval entirely.⁹

The 2018 isoxazoline alert is a good example of this system in action. The drugs were approved based on clinical trial data that showed them to be safe and effective. After millions of real-world doses, a pattern of neurological events emerged that was consistent enough across the isoxazoline class to warrant the label update. That does not mean the pre-approval trials were flawed; rare side effects sometimes only become visible when a very large population uses a product. The system caught the signal and acted on it, which is what pharmacovigilance is supposed to do.

If your dog has an unusual reaction after taking Simparica Trio, you can report it directly to the FDA through their online Safety Reporting Portal or by calling the CVM. You can also report it through your veterinarian or through the manufacturer. These reports matter: the more data the system has, the faster it can detect new safety signals.

Why Tick and Flea Prevention Still Matters

The side-effect conversation can sometimes overshadow the reason these products exist. Tick-borne diseases are a serious and growing threat to dogs in many parts of the world, and the speed at which pathogens transmit after a tick attaches is faster than most people realize. In an experimental model testing how quickly key tick-borne bacteria can transmit, Ehrlichia canis was detected in blood within about three to six hours after tick attachment, and Anaplasma phagocytophilum within roughly 12 to 15 hours. Borrelia burgdorferi, the bacterium behind Lyme disease, took longer at around 42 to 45 hours in blood, though it showed up on tissue surfaces much sooner.¹⁰

Those transmission windows are why a product that kills ticks quickly after they begin feeding can make a real difference. A tick that attaches and begins feeding but dies within hours has less time to transmit bacteria than one that feeds undisturbed for a day or more. Simparica Trio’s sarolaner component is designed to kill ticks rapidly once they start feeding, which shrinks that transmission window. No product prevents a tick from landing on your dog or biting in the first place; what these products do is kill the tick fast enough to reduce the chance of disease transfer. Checking your dog after walks in tick-heavy areas remains important as a complement to any preventive.

When Simparica Trio May Not Be the Right Choice

No single product is perfect for every dog. There are several situations where your vet might steer you toward a different option:

Seizure history: Dogs with epilepsy or a history of seizures are the population the FDA warning is most pointed about. An isoxazoline product may still be used in these dogs if the vet judges the benefits outweigh the risks, but it requires an explicit conversation and possibly closer monitoring.
Very small or underweight puppies: If a puppy is close to the minimum weight threshold, dosing becomes trickier. Some vets prefer a topical flea product and a separate heartworm preventive until the puppy is a bit bigger.
ABCB1-mutant breeds on other medications: If your Collie or Australian Shepherd is already taking drugs that interact with the ABCB1 transporter, adding Simparica Trio introduces another variable. Your vet can review the full medication list.
Dogs with severe liver disease: Sarolaner is metabolized in the liver, so dogs with compromised liver function may not clear the drug as efficiently. Bloodwork can help your vet assess this.

For the vast majority of healthy dogs over the minimum age and weight, the clinical evidence shows Simparica Trio to be a well-tolerated option. The side effects that most owners encounter, if any, are mild and temporary digestive upset. The neurological events that triggered the FDA alert are real but rare, and the labeling update means every product box now reminds you to discuss the risk with your vet. Bringing up your dog’s full health history, breed background, and any prior reactions to medications is the single most useful thing you can do at that appointment.

Isoxazolines in Non-Dog Species

One area where the safety picture gets murkier is the use of isoxazoline drugs in species they were never designed for. Fluralaner, a related isoxazoline marketed under a different brand, has been studied in at least 14 mammalian species beyond dogs and cats, including wildlife and exotic animals. A systematic review of that off-label use found fluralaner to be moderately effective against ectoparasites in captive settings but noted that safety reporting was inconsistent: most studies were small, and many did not explicitly report whether adverse effects occurred. One study documented signs of severe neurological toxicity in a non-target species.¹¹

Simparica Trio is approved exclusively for dogs. The temptation to use leftover tablets on a cat, a ferret, or another pet should be resisted. Cats in particular metabolize certain compounds differently from dogs, and a dose that is safe for a ten-pound dog could be harmful to a ten-pound cat. If you need parasite prevention for a non-dog pet, separate species-specific products exist, and your vet can point you to the right one.